Bcr Activators
Bcr activators are a category of chemical agents that target the biological activity of the breakpoint cluster region protein, commonly abbreviated as BCR. This protein is a significant player in cellular processes, particularly in the signal transduction pathways that influence cell proliferation and differentiation. BCR, as a multifunctional protein, has a role in the regulation of various signaling molecules and is known to interact with a diverse array of partners within the cell, acting as a scaffold for the assembly of complex signaling networks. Bcr activators are designed to modulate the function of BCR, which, by virtue of their action, can lead to the modulation of these signaling pathways. The chemical structure of Bcr activators is diverse, reflecting the complexity of the protein's interaction domains and the necessity for specificity in the modulation of its activity.
The action of Bcr activators revolves around the alteration of the BCR protein's state, which can include changes in its phosphorylation status, conformation, or its ability to interact with other cellular components. By influencing BCR activity, these molecules can affect a range of intracellular signaling cascades that are critical for the maintenance of cellular homeostasis and the regulation of cell behavior. The mechanisms of action for Bcr activators might involve direct binding to the BCR protein, hence modifying its direct function, or they might interact with regulatory regions or cofactors that control BCR activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that indirectly influences Bcr activation by targeting the Bcr-Abl fusion protein. By inhibiting the constitutively active Bcr-Abl kinase, Imatinib disrupts downstream signaling cascades involved in cellular proliferation and survival, ultimately modulating Bcr activity in the context of Bcr-Abl-driven malignancies. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, another tyrosine kinase inhibitor, affects Bcr activation by inhibiting Bcr-Abl and other Src family kinases. Its broader spectrum of kinase inhibition compared to Imatinib makes Dasatinib a potent modulator of Bcr signaling pathways. By interfering with key kinases, Dasatinib influences the phosphorylation events associated with Bcr, thus impacting its activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a tyrosine kinase inhibitor with specificity for Bcr-Abl, inhibiting its kinase activity. By directly targeting the Bcr-Abl fusion protein, Nilotinib interferes with the aberrant signaling pathways associated with Bcr-Abl, indirectly impacting Bcr activation. This makes Nilotinib a crucial tool in modulating Bcr function in the context of Bcr-Abl-driven diseases. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a tyrosine kinase inhibitor with activity against Bcr-Abl, including the T315I mutant, rendering it effective in cases of resistance. By inhibiting Bcr-Abl, Ponatinib disrupts the aberrant signaling cascades associated with Bcr, influencing its activity in the context of Bcr-Abl-driven malignancies. The ability to target resistant mutants enhances Ponatinib's impact on Bcr modulation. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
R788 is a spleen tyrosine kinase (Syk) inhibitor that indirectly affects Bcr activation by targeting upstream signaling events. By inhibiting Syk, R788 interferes with B-cell receptor (BCR) signaling pathways, leading to downstream effects on Bcr. This modulation of Bcr activity is part of the broader impact of Syk inhibition on BCR-mediated signaling cascades. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
ACP-196, also known as acalabrutinib, is a Bruton's tyrosine kinase (BTK) inhibitor that indirectly influences Bcr activation. By targeting BTK, a key kinase in BCR signaling, ACP-196 disrupts downstream events initiated by Bcr, leading to modulation of its activity. The inhibition of BTK is part of the strategy to interfere with BCR signaling and impact Bcr function within B-cell malignancies. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is another BTK inhibitor that indirectly affects Bcr activation. By inhibiting BTK, Ibrutinib disrupts BCR signaling pathways, leading to downstream effects on Bcr. The modulation of Bcr activity is integral to the therapeutic effects of Ibrutinib, particularly in the context of B-cell malignancies where aberrant BCR signaling plays a pivotal role. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Idelalisib is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly influences Bcr activation by targeting the PI3K pathway. By inhibiting PI3K, Idelalisib disrupts downstream signaling events, including those initiated by Bcr, leading to alterations in Bcr activity. This broader impact on the PI3K pathway contributes to the modulation of Bcr function within the context of B-cell malignancies. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 is a B-cell lymphoma-2 (Bcl-2) inhibitor that indirectly affects Bcr activation by targeting apoptotic pathways. By inhibiting Bcl-2, ABT-199 promotes apoptosis in BCR-dependent B-cell malignancies, indirectly impacting Bcr activity through the induction of cell death. The modulation of apoptotic pathways is a strategy to influence Bcr function in the context of BCR-driven malignancies. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that indirectly influences Bcr activation by targeting upstream signaling events. By inhibiting JAK, Ruxolitinib interferes with downstream signaling pathways, including those initiated by Bcr, leading to alterations in Bcr activity. This broader impact on JAK-STAT signaling contributes to the modulation of Bcr function within the context of hematological malignancies. | ||||||